Literature DB >> 26215469

Pharmacological approaches in either intermittent or permanent hypoxia: A tale of two exposures.

E A Herrera1, J G Farías2, G Ebensperger1, R V Reyes1, A J Llanos1, R L Castillo3.   

Abstract

Hypoxia induces several responses at cardiovascular, pulmonary and reproductive levels, which may lead to chronic diseases. This is relevant in human populations exposed to high altitude (HA), in either chronic continuous (permanent inhabitants) or intermittent fashion (HA workers, tourists and mountaineers). In Chile, it is estimated that 1.000.000 people live at highlands and more than 55.000 work in HA shifts. Initial responses to hypoxia are compensatory and induce activation of cardioprotective mechanisms, such as those seen under intermittent hypobaric (IH) hypoxia, events that could mediate preconditioning. However, whenever hypoxia is prolonged, the chronic activation of cellular responses induces long-lasting modifications that may result in acclimatization or produce maladaptive changes with increase in cardiovascular risk. HA exposure during pregnancy induces hypoxia and oxidative stress, which in turn may promote cellular responses and epigenetic modifications resulting in severe impairment in growth and development. Sadly, this condition is accompanied with an increased fetal and neonatal morbi-mortality. Further, developmental hypoxia may program cardio-pulmonary circulations later in postnatal life, ending in vascular structural and functional alterations with augmented risk on pulmonary and cardiovascular failure. Additionally, permanent HA inhabitants have augmented risk and prevalence of chronic hypoxic pulmonary hypertension, right ventricular hypertrophy and cardiopulmonary remodeling. Similar responses are seen in adults that are intermittently exposed to chronic hypoxia (CH) such as shift workers in HA areas. The mechanisms involved determining the immediate, short and long-lasting effects are still unclear. For several years, the study of the responses to hypoxic insults and pharmacological targets has been the motivation of our group. This review describes some of the mechanisms underlying hypoxic responses and potential therapeutic approaches with antioxidants such as melatonin, ascorbate, omega 3 (Ω3) or compounds that increase the nitric oxide (NO) bioavailability.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  High altitude; Hypoxia; Melatonin; Nitric oxide; Omega 3; Pulmonary hypertension

Mesh:

Substances:

Year:  2015        PMID: 26215469     DOI: 10.1016/j.phrs.2015.07.011

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  10 in total

1.  Melatonin protected cardiac microvascular endothelial cells against oxidative stress injury via suppression of IP3R-[Ca2+]c/VDAC-[Ca2+]m axis by activation of MAPK/ERK signaling pathway.

Authors:  Hang Zhu; Qinhua Jin; Yang Li; Qiang Ma; Jing Wang; Dandan Li; Hao Zhou; Yundai Chen
Journal:  Cell Stress Chaperones       Date:  2017-07-01       Impact factor: 3.667

2.  Antenatal melatonin modulates an enhanced antioxidant/pro-oxidant ratio in pulmonary hypertensive newborn sheep.

Authors:  Alejandro Gonzalez-Candia; Marcelino Veliz; Catalina Carrasco-Pozo; Rodrigo L Castillo; J Cesar Cárdenas; Germán Ebensperger; Roberto V Reyes; Aníbal J Llanos; Emilio A Herrera
Journal:  Redox Biol       Date:  2019-01-29       Impact factor: 11.799

3.  The Action of 2-Aminoethyldiphenyl Borinate on the Pulmonary Arterial Hypertension and Remodeling of High-Altitude Hypoxemic Lambs.

Authors:  Sebastián Castillo-Galán; Daniela Parrau; Ismael Hernández; Sebastián Quezada; Marcela Díaz; Germán Ebensperger; Emilio A Herrera; Fernando A Moraga; Rodrigo Iturriaga; Aníbal J Llanos; Roberto V Reyes
Journal:  Front Physiol       Date:  2022-01-10       Impact factor: 4.566

4.  Biomechanical and structural responses of the aorta to intermittent hypobaric hypoxia in a rat model.

Authors:  Andrés Utrera; Álvaro Navarrete; Alejandro González-Candia; Claudio García-Herrera; Emilio A Herrera
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.379

5.  Cardioprotective Antioxidant and Anti-Inflammatory Mechanisms Induced by Intermittent Hypobaric Hypoxia.

Authors:  Alejandro González-Candia; Alejandro A Candia; Adolfo Paz; Fuad Mobarec; Rodrigo Urbina-Varela; Andrea Del Campo; Emilio A Herrera; Rodrigo L Castillo
Journal:  Antioxidants (Basel)       Date:  2022-05-25

6.  Melatonin Decreases Pulmonary Vascular Remodeling and Oxygen Sensitivity in Pulmonary Hypertensive Newborn Lambs.

Authors:  Cristian R Astorga; Alejandro González-Candia; Alejandro A Candia; Esteban G Figueroa; Daniel Cañas; Germán Ebensperger; Roberto V Reyes; Aníbal J Llanos; Emilio A Herrera
Journal:  Front Physiol       Date:  2018-03-06       Impact factor: 4.566

7.  Mechanisms of Cardiovascular Protection Associated with Intermittent Hypobaric Hypoxia Exposure in a Rat Model: Role of Oxidative Stress.

Authors:  Miguel Aguilar; Alejandro González-Candia; Jorge Rodríguez; Catalina Carrasco-Pozo; Daniel Cañas; Claudio García-Herrera; Emilio A Herrera; Rodrigo L Castillo
Journal:  Int J Mol Sci       Date:  2018-01-26       Impact factor: 5.923

Review 8.  Revisiting the Role of TRP, Orai, and ASIC Channels in the Pulmonary Arterial Response to Hypoxia.

Authors:  Roberto V Reyes; Sebastián Castillo-Galán; Ismael Hernandez; Emilio A Herrera; Germán Ebensperger; Aníbal J Llanos
Journal:  Front Physiol       Date:  2018-05-07       Impact factor: 4.566

9.  Biomechanical characterization of the passive response of the thoracic aorta in chronic hypoxic newborn lambs using an evolutionary strategy.

Authors:  Eugenio Rivera; Claudio Canales; Matías Pacheco; Claudio García-Herrera; Demetrio Macías; Diego J Celentano; Emilio A Herrera
Journal:  Sci Rep       Date:  2021-07-06       Impact factor: 4.379

Review 10.  High Altitude Pregnancies and Vascular Dysfunction: Observations From Latin American Studies.

Authors:  Alejandro Gonzalez-Candia; Emilio A Herrera
Journal:  Front Physiol       Date:  2021-12-07       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.